Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Did not receive funding
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
We propose to evaluate the interaction between expectations of receiving stimulants, neurophysiological activity and enhancement of cognitive performance using fMRI.
Participants will then be randomized in a balanced placebo design (BPD) crossing medication (10 mg of mixed amphetamine salts vs placebo) and expectancy (told active medication vs placebo medication), resulting in 4 different conditions 1) mixed amphetamine salts/told stimulant medication; 2) placebo/told stimulant medication; 3) mixed amphetamine salts/told placebo; and 4) placebo/told placebo). Participants will be assigned to four scanning sessions scheduled one week apart and will experience each condition once counterbalanced across participants. Participants will be administered cognitive tasks in and out of the scanner to determine the effects of medication vs expectancy.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Adderall/Truth | Experimental | Participants will be told they are receiving Adderall and will actually be administered Adderall. |
|
| Adderall/Deception | Experimental | Participants will be told they are receiving Adderall and will actually be administered placebo |
|
| Placebo/Truth | Placebo Comparator | Participants will be told they are receiving placebo and will actually be administered placebo. |
|
| Placebo/Deception | Experimental | Participants will be told they are receiving placebo and will actually be administered Adderall |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Adderall 10Mg Tablet | Drug | Participants will be administered Adderall |
|
| Measure | Description | Time Frame |
|---|---|---|
| How expectancy will affect cognitive performance | Using a balanced placebo design, participants will be either administered mixed amphetamine salts or placebo. Their cognitive performance will be assessed in the MRI scanner. The main outcome measure is how the expectancy of stimulants will affect cognitive performance. | 120 minutes |
| The impact that stimulants vs. placebo have on the neural circuitry | Using a balanced placebo design, participants will be either administered mixed amphetamine salts or placebo. Their cognitive performance will be assessed in the MRI scanner. This outcome measure is to determine the impact stimulant administration and expectancy of stimulants have on the neural circuitry that supports sustained attention, inhibitory control, and verbal memory processes. | 120 minutes |
| Determine whether stimulant administration and expectancy for stimulants modify the functional connectivity of brain networks | Using a balanced placebo design, participants will be either administered mixed amphetamine salts or placebo. Their cognitive performance will be assessed in the MRI scanner. This outcome measure is to determine whether stimulant administration and expectancy for stimulants modify the functional connectivity of brain networks that support cognitive processes under investigation. | 120 minutes |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Karen Cropsey, PsyD | University of Alabama at Birmingham | Principal Investigator |
| David Knight, PhD | University of Alabama at Birmingham | Principal Investigator |
Not provided
Not provided
| ID | Term |
|---|---|
| D008192 | Deception |
| ID | Term |
|---|---|
| D012919 | Social Behavior |
| D001519 | Behavior |
Not provided
Not provided
| ID | Term |
|---|---|
| C090411 | Adderall |
| D013607 | Tablets |
| ID | Term |
|---|---|
| D004304 | Dosage Forms |
| D004364 | Pharmaceutical Preparations |
Not provided
Not provided
2 X 2, within-subjects, balanced placebo design
Not provided
Not provided
This will be a double-blind study. Research assistants will administer capsules, and based on package labeling, tell the participant if they are being administered Adderall or placebo. However, researchers and participants will be blind to which medication is actually being administered.
| Placebo | Drug | Participants will be administered placebo |
|